Substance Use in Pregnancy and its Association With Cardiovascular Events
Affiliation
Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Arizona, PhoenixIssue Date
2023-09-14
Metadata
Show full item recordPublisher
Elsevier B.V.Citation
Evans, K, Wu, P, Mamas, M. et al. Substance Use in Pregnancy and its Association With Cardiovascular Events. JACC Adv. 2023 Oct, 2 (8). https://doi.org/10.1016/j.jacadv.2023.100619Journal
JACC: AdvancesRights
© 2023 The Authors. Published by Elseiver on Behalf of the American College of Cardiology Foundation. This is an Open Access article under the CC BY NC-ND License (http://creativecommons.org/licenses/by-nc-nd/4.0/).Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Background: Substance use and cardiovascular (CV) events are increasing among pregnant women in the United States, but association between substance use in pregnancy and CV events remains unknown. Objectives: The purpose of this study was to examine the association between substance use and acute CV events in pregnancy. Methods: We identified all women with a delivery hospitalization between 2004 and 2018 in the Nationwide Inpatient Sample, stratified on the presence or absence of substance use. The primary outcome was any acute CV event, defined as the presence of: acute myocardial infarction, stroke, arrhythmia, endocarditis, acute cardiomyopathy or heart failure, or cardiac arrest. Secondary outcomes were individual acute CV events, major adverse cardiac events, and maternal mortality. The association between substance use and outcomes were examined using multivariable logistical regression. Results: A total of 60,014,368 delivery hospitalizations occurred from 2004 to 2018, with substance use complicating 955,531 (1.6%) deliveries. Substance use was independently associated with CV events (adjusted odds ratio [aOR]: 1.61; 95% CI: 1.53-1.70; P < 0.001), major adverse cardiac events (aOR: 1.53; 95% CI: 1.46-1.61; P < 0.001), and maternal mortality (aOR: 2.65; 95% CI: 2.15-3.25; P < 0.001) during delivery hospitalization. All individual substances had an increased association with CV events; however, amphetamine/methamphetamine had the strongest association (aOR: 2.71; 95% CI: 2.35-3.12; P < 0.001). All substances other than cocaine and cannabis had a significant association with maternal death. Conclusions: Substance use has a strong association with acute CV events and maternal mortality during hospitalization for delivery and women with substance use warrant increased surveillance for CV events during this time. © 2023 The AuthorsNote
Open access journalISSN
2772-963XVersion
Final Published Versionae974a485f413a2113503eed53cd6c53
10.1016/j.jacadv.2023.100619
Scopus Count
Collections
Except where otherwise noted, this item's license is described as © 2023 The Authors. Published by Elseiver on Behalf of the American College of Cardiology Foundation. This is an Open Access article under the CC BY NC-ND License (http://creativecommons.org/licenses/by-nc-nd/4.0/).